Phathom Pharmaceuticals, Inc. — Form 8-K Summary
Reporting date: July 14, 2023; filed July 17, 2023. The filing reports completion of a one-time stock option exchange program under Item 5.02.
Business Context and Reporting Period
Phathom Pharmaceuticals, Inc. is a Delaware corporation whose common stock trades on Nasdaq under the symbol PHAT. The filing does not report quarterly or annual operating results; it addresses an equity compensation transaction involving eligible employees and consultants, including executive officers.
Key Transaction Details
- The Option Exchange expired on July 14, 2023, at 11:59 p.m. Eastern Time.
- Options to purchase 2,406,622 shares were accepted for exchange, representing approximately 99.2% of eligible options.
- All surrendered options were cancelled, and approximately 1,203,341 new restricted stock units were issued under the 2019 Incentive Award Plan.
- The exchange ratio was one RSU for every two shares underlying surrendered options.
- The new RSUs vest in three equal installments on the first three anniversaries of completion, subject to continued service.
| Named Executive Officer | Surrendered Options | New RSUs |
|---|---|---|
| Terrie Curran | 400,000 | 200,000 |
| Azmi Nabulsi, M.D., M.P.H. | 220,000 | 110,000 |
| Molly Henderson | None | None |
Financial Metrics and Material Changes
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, guidance, or other operating metrics. It also does not provide a clear dollar-value impact of the exchange on stock-based compensation or shareholders’ equity.
Relative to the prior period, the material change is the cancellation of substantially all eligible options and issuance of new RSUs. The company stated that the surrendered options had exercise prices significantly above recent trading prices.
Outlook, Risks, and Unusual Items
The transaction is intended to replace substantially out-of-the-money options with RSUs subject to a new three-year vesting schedule. The filing does not provide broader business guidance or financial outlook.
Risks identified include failure to complete or obtain the intended benefits of the exchange, termination or failure of transaction conditions, employee retention and hiring effects, disruption to business relationships or operations, management distraction, potential stockholder litigation and related costs, and general risks described in the company’s Form 10-K for the year ended December 31, 2022 and other SEC filings.
Investor Verification Checklist
- Verify the final number and terms of RSUs issued in the company’s equity compensation disclosures.
- Assess the future stock-based compensation expense and dilution associated with the new RSUs.
- Review the Schedule TO, offer to exchange, amendments, and related materials for complete transaction terms.
- Review subsequent SEC filings for any effects on share count, compensation expense, liquidity, or employee retention.
- Review the company’s Form 10-K and other SEC filings for broader operating, financing, and clinical-development risks.